Kai Yeung, PharmD, PhD

Yeung_Kai__205x293.jpg

“My work helps to maximize the benefit to society for every dollar spent on health care.”

Kai Yeung, PharmD, PhD

Assistant Investigator, Kaiser Permanente Washington Health Research Institute

Biography

Kai Yeung, PharmD, PhD, is a pharmacist and pharmaceutical economist with expertise in patient medication-use behaviors, insurance design, and outcomes research. His objective is to develop and evaluate incentives to encourage high-value use of health care services. Dr. Yeung has conducted research evaluating policies focused on specialty drug access, value-based insurance design, the consequences of insurance switching, and financial incentives. He combines applied econometric and cost-effectiveness analysis tools with a clinical understanding of prescription drugs and health insurance design to gain new insights in these areas.

Dr. Yeung has a line of research on designing and evaluating policies that align patient prescription drug out-of-pocket costs with estimated value using cost-effectiveness analysis. He has used econometric methods to quantify the impact of a value-based formulary on patient medication-utilization behavior, health outcomes and health care expenditures from patient and health care payer perspectives. For this work, Dr. Yeung successfully competed for two research grants: a multidisciplinary research training grant from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) and a health services research dissertation grant from the Agency for Healthcare Research and Quality (AHRQ). Different parts of this project were recognized by the International Society for Pharmacoeconomics and Outcomes Research 2014 and 2015 annual meetings as the best student podium presentation award, and the Vancouver Health Economics Methodology 2016 meeting as the best student paper award. Dr. Yeung continues to innovate in the generation and evaluation of this type of benefit design.

Dr. Yeung received his PhD in pharmaceutical economics from the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington and his PharmD from the University of Southern California. During his PharmD training, Dr. Yeung cultivated a broad perspective on the expanded use of evidence and analytics in decision-making, giving him experience in working with a diverse group of health care stakeholders, including:

  • patients (through the practice of clinical pharmacy),
  • health care payers (through Kaiser Permanente Drug Information Services),
  • federal agencies (through AHRQ and U.S. Food and Drug Administration),
  • professional organizations (through the Academy for Managed Care Pharmacy), and
  • international technology assessment organizations (through NIH and Clinical Excellence, UK).

Research interests and experience

  • Health Services and Economics

    Pharmacy benefit design, applied econometrics, healthcare costs, value-based insurance design, cost-effectiveness analysis, behavioral economics, alternative payment models, health policy evaluation

  • Medication Use & Patient Safety

    Pharmacoepidemiology of opioid use, identification of early onset Alzheimer’s disease

  • Behavior Change

    Design and evaluation of incentives for medication adherence

  • Preventive Medicine

    Patient and physician shared savings models to incentivize healthy behavior

  • Addictions

    Prevention and treatment

Recent publications

Yeung K, Dorsey CN, Mettert K. Effect of new Medicare enrollment on health, healthcare utilization, and cost: a scoping review. J Am Geriatr Soc. 2021 Mar 15. doi: 10.1111/jgs.17113. [Epub ahead of print]. PubMed

Li M, Yeung K. Managing high-priced biologic agents: challenges and potential solutions. J Manag Care Spec Pharm. 2021;27(3):411-414. doi: 10.18553/jmcp.2021.27.3.411. PubMed

McCurry SM, Zhu W, Von Korff M, Wellman R, Morin CM, Thakral M, Yeung K, Vitiello MV. Effect of telephone cognitive behavioral therapy for insomnia in older adults with osteoarthritis pain: a randomized clinical trial. JAMA Intern Med. 2021 Feb 22:e209049. doi: 10.1001/jamainternmed.2020.9049. [Epub ahead of print]. PubMed

Yeung K, Richards J, Goemer E, Lozano P, Lapham G, Williams E, Glass J, Lee A, Achtmeyer C, Caldeiro R, Parrish R, Bradley K. Costs of using evidence-based implementation strategies for behavioral health integration in a large primary care system. Health Serv Res. 2020 Dec;55(6):913-923. doi: 10.1111/1475-6773.13592. PubMed

Yeung K, Barthold D, Dusetzina SB, Basu A. Patient and plan spending after state specialty-drug out-of-pocket spending caps. N Engl J Med. 2020 Aug 6;383(6):558-566. doi: 10.1056/NEJMsa1910366. PubMed

 

Research

Insomnia-phone-therapy-elderly-blog_1col.jpg

Phone therapy for insomnia shown to improve sleep

A study among KP members with sleep problems and osteoarthritis shows promise for overcoming obstacles to treatment.

healthy findings blog

Blog_-_NEJM_perspective_pragmatic_trial_-_Simon_-_1_column.jpg

Pandemic highlights need for pragmatic clinical trials

Now more than ever we can benefit from studies embedded in health-care systems to answer common clinical questions.

Mental Health

Blog_Behavioral_Health_Integration_Kai_Yeung-1col.jpg

What’s the cost of mental health integration?

Kaiser Permanente Washington shows price may not be a barrier to primary care implementation, Dr. Kai Yeung reports.

KPWHRI In the Media

Kai Yeung on incentives to encourage high-value use of health care

Drug-cost offsets seem to take some pressure off patients’ wallets

Physicians Weekly, April 1, 2021

KPWHRI In the Media

Which prescription drug policies control patient costs?

NEJM study: Caps on out-of-pocket costs for specialty drugs reduce patient spend by 32%

Managed Healthcare Executive, Aug 5, 2020